|
Market Closed -
Nasdaq
20:30:00 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 1.400 USD | -11.37% |
|
-13.56% | -94.04% |
| 10-09 | BioRestorative Therapies, Inc. Announces Board and Committee Changes | CI |
| 10-06 | Maxim Downgrades BioRestorative Therapies to Hold From Buy | MT |
Projected Income Statement: BioRestorative Therapies, Inc.
Annual
Quarterly
Annual
Quarterly
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.046 | 0.1198 | 0.1458 | 0.401 | 0.3597 | 0.31 | 1.5 | 2.5 |
| Change | - | 160.43% | 21.7% | 175.03% | -10.3% | -13.82% | 383.87% | 66.67% |
| EBITDA | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| EBIT 1 | -26.31 | -18.97 | -15.22 | -11.56 | -15.65 | -16.82 | -16.54 | -16.48 |
| Change | - | 27.88% | 19.78% | 24.08% | -35.41% | -7.47% | 1.67% | 0.31% |
| Interest Paid | - | 0.0116 | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -44.3 | -18.49 | -14.42 | -8.979 | -14.24 | -16.64 | -16.32 | -16.2 |
| Change | - | 58.25% | 22.06% | 37.71% | -58.61% | -16.81% | 1.91% | 0.72% |
| Net income 1 | -44.3 | -18.49 | -14.42 | -8.979 | -14.24 | -16.64 | -16.32 | -16.2 |
| Change | - | 58.25% | 22.06% | 37.71% | -58.61% | -16.81% | 1.91% | 0.72% |
| Announcement Date | 30/03/22 | 27/03/23 | 01/04/24 | 28/03/25 | 26/03/26 | - | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: BioRestorative Therapies, Inc.
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Announcement Date | 30/03/22 | 27/03/23 | 01/04/24 | 28/03/25 | 26/03/26 | - | - | - |
Estimates
Cash Flow Forecast: BioRestorative Therapies, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| CAPEX 1 | - | 0.0307 | 0.2652 | 0.171 | 0.1062 | 0.1161 |
| Change | - | - | 765.1% | -35.51% | -37.92% | 9.3% |
| Free Cash Flow (FCF) 1 | -6.312 | 5.705 | 0.6117 | -1.081 | -3.11 | -6.2 |
| Change | - | 190.38% | -89.28% | -276.67% | -187.81% | -99.34% |
| Announcement Date | 30/04/21 | 30/03/22 | 27/03/23 | 01/04/24 | 28/03/25 | 26/03/26 |
1USD in Million
Estimates
Forecast Financial Ratios: BioRestorative Therapies, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
| EBITDA Margin (%) | - | - | - | - | - | - | - | - | - |
| EBIT Margin (%) | - | -57,191.02% | -15,838.09% | -10,439.49% | -2,881.59% | -4,350.05% | -5,424.52% | -1,102.33% | -659.32% |
| EBT Margin (%) | - | -96,311.52% | -15,438.04% | -9,887.16% | -2,239.25% | -3,959.41% | -5,366.45% | -1,087.93% | -648.08% |
| Net margin (%) | - | -96,311.52% | -15,438.04% | -9,887.16% | -2,239.25% | -3,959.41% | -5,366.45% | -1,087.93% | -648.08% |
| FCF margin (%) | - | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - | - |
Profitability | |||||||||
| ROA | -59.18% | -122.7% | -60.99% | -65.5% | -58.03% | -119.56% | - | - | - |
| ROE | 159.81% | -437.23% | -98.83% | -105.3% | -96.89% | -320.47% | - | - | - |
Financial Health | |||||||||
| Leverage (Debt/EBITDA) | -0.66x | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | -0.27x | - | - | - | - | - | - | - | - |
Capital Intensity | |||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - | - |
Items per share | |||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| EPS 1 | - | -746 | -102.2 | -68.4 | -23.2 | -31.6 | -13.2 | -10.4 | -9.8 |
| Change | - | - | 86.3% | 33.07% | 66.08% | -36.21% | 58.23% | 21.21% | 5.77% |
| Nbr of stocks (in thousands) | - | 175 | 184 | 235 | 346 | 444 | 1,274 | 1,274 | 1,274 |
| Announcement Date | - | 30/03/22 | 27/03/23 | 01/04/24 | 28/03/25 | 26/03/26 | - | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -0.11x | -0.13x |
| PBR | - | - |
| EV / Sales | 5.75x | 1.19x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.400USD
Average target price
300.00USD
Spread / Average Target
+21,323.98%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BRTX Stock
- Financials BioRestorative Therapies, Inc.
Select your edition
All financial news and data tailored to specific country editions
















